Celyad OncologyCLYYF 28 Interest Coverage is 96.77 as of Dec. 2025. GuruFocus rates CLYYF with a GF Score™ of 28/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 377 Biotechnology companies, Celyad Oncology ranks worse than 265251.72% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Celyad Oncology's
Operating Income
for the
six
months ended in Dec. 2025 was $2.52 Mil. Celyad Oncology's Interest Expense for the
six
months ended in Dec. 2025 was $-0.03 Mil.
Celyad Oncology's interest coverage for the quarter that ended in Dec. 2025 was 96.77.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Celyad Oncology's Interest Coverage or its related term are showing as below:
CLYYF's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Celyad Oncology Interest Coverage Related Terms
Celyad Oncology Interest Coverage Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CLYYF vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Celyad Oncology's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a Interest Coverage of 96.77 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Celyad Oncology and its competitors. According to the industry distribution chart, Celyad Oncology ranks #999999 out of 377 companies in the Biotechnology industry.
Is Celyad Oncology's Interest Coverage too high?
Celyad Oncology's current Interest Coverage is 96.77. The Biotechnology industry median Interest Coverage is 106.07. Celyad Oncology's value of 96.77 is 8.8% below this industry median. Based on the distribution chart, Celyad Oncology ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #999999 out of 377 companies for Interest Coverage. This places Celyad Oncology in the lower half of its industry. The industry median Interest Coverage is 106.07. Celyad Oncology's value of 96.77 is 8.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celyad Oncology's current Interest Coverage of 96.77 is 8.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Celyad Oncology and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current Interest Coverage is 96.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.25 — trading 66.7% above its estimated fair value. The current Interest Coverage is 96.77 and 8.8% below the Biotechnology industry median of 106.07. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Interest Coverage is 96.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued.
The current stock price of $0.25 is trading 66.7% above its estimated GF Value™ of $0.15.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
Interest Coverage: 96.77
GF Value™: $0.15 vs. price of $0.25 (66.7% above fair value)
Industry Position: 8.8% below the Biotechnology median (#999999 of 377)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
